Compare YMT & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | BBLG |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.5M |
| IPO Year | 2023 | 2014 |
| Metric | YMT | BBLG |
|---|---|---|
| Price | $0.22 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 849.5K | 166.0K |
| Earning Date | 06-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.62 |
| 52 Week High | $2.85 | $4.13 |
| Indicator | YMT | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 27.22 |
| Support Level | $0.14 | N/A |
| Resistance Level | $0.35 | $1.38 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 5.40 | 10.70 |
Yimutian Inc operates an agricultural B2B platform in China. It provides a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching and matching to transaction facilitation and settlement, through its Yimutian App and Douniu App. Additionally, leveraging its industry experience and market insights, the company has ventured into the realm of smart farming and agricultural sourcing and trading, further broadening its commercialization channels and animating its other business lines. The company operates as a single operating and reportable segment, as it offers a unified set of products and services mainly related to the provision of digital agricultural transaction services.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.